StockNews.AI
GH
StockNews.AI
201 days

Guardant Health to Report Fourth Quarter and Full Year 2024 Financial Results on February 20, 2025

1. Guardant Health will report Q4 2024 results on February 20, 2025. 2. Management will host a conference call post-results for discussions. 3. Guardant focuses on precision oncology to improve patient outcomes. 4. The company utilizes advanced testing, real-world data, and AI. 5. Financial results will indicate company performance and market trends.

6m saved
Insight
Article

FAQ

Why Neutral?

Scheduled financial results typically do not create immediate price volatility.

How important is it?

Earnings reports significantly influence stock prices, albeit with expected volatility.

Why Short Term?

The initial impact will be observed shortly after results are released.

Related Companies

Guardant Health to Report Fourth Quarter and Full Year 2024 Financial Results on February 20, 2025

PALO ALTO, Calif.--( )--Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, today announced it will report financial results for the fourth quarter and full year 2024 after market close on Thursday, February 20, 2025. Company management will webcast a corresponding conference call beginning at 1:30 p.m. Pacific Time / 4:30 p.m. Eastern Time.

Live audio of the webcast will be available on the “Investors” section of the company website at: www.guardanthealth.com. The webcast will be archived and available for replay after the event.

About Guardant Health

Guardant Health is a leading precision oncology company focused on guarding wellness and giving every person more time free from cancer. Founded in 2012, Guardant is transforming patient care and accelerating new cancer therapies by providing critical insights into what drives disease through its advanced blood and tissue tests, real-world data and AI analytics. Guardant tests help improve outcomes across all stages of care, including screening to find cancer early, monitoring for recurrence in early-stage cancer, and treatment selection for patients with advanced cancer. For more information, visit guardanthealth.com and follow the company on LinkedIn, X (Twitter) and Facebook.

Contacts

Investor Contact:
Zarak Khurshid
investors@guardanthealth.com

Media Contact:
Melissa Marasco
press@guardanthealth.com
+1 650-647-3711

Related News